Get access

Results of the citalopram to enhance cognition in Huntington disease trial

Authors


  • Clinical trial registry: A randomized, placebo-controlled pilot study in Huntington's disease: citalopram to enhance cognition in HD (CIT-HD). http://clinicaltrials.gov/show/NCT00271596.

  • Funding agencies: National Institutes of Health (NS055733-01 to L.J.B.); CHDI Foundation; University of Iowa Center for Clinical and Translational Research; Huntington Disease Society of America (to J.S.P.) for the University of Iowa HD Center of Excellence; National HD Research Roster.

  • Relevant conflicts of interest/financial disclosures: Nothing to report.

  • Full financial disclosures and author roles may be found in the online version of this article.

ABSTRACT

Background

The objective of this study was to evaluate citalopram for executive functioning in Huntington's disease (HD).

Methods

The study was randomized, double-blind, and placebo-controlled. Thirty-three adults with HD, cognitive complaints, and no depression (Hamilton Depression [HAM-D] rating scale ≤12) were administered citalopram 20 mg or placebo (7 visits, 20 weeks), with practice and placebo run-ins. The primary outcome was change in executive functioning.

Results

The intent to treat analysis was controlled for practice effects, comparing visits 1 and 2 to visits 5 and 6 for citalopram versus placebo. There were no significant benefits on the executive function composite (treatment-placebo mean difference −0.167; 95% confidence interval [CI], −0.361 to 0.028; P = .092). Citalopram participants showed improved clinician-rated depression symptoms on the HAM-D (t = −2.02; P = 0.05). There were no group differences on motor ratings, self-reported executive functions, psychiatric symptoms, or functional status.

Conclusions

There was no evidence that short-term treatment with citalopram improved executive functions in HD. Despite excluding patients with active depression, participants on citalopram showed improved mood, raising the possibility of efficacy for subsyndromal depression in HD. © 2013 International Parkinson and Movement Disorder Society

Get access to the full text of this article

Ancillary